-
QL Biopharm Raises Series B Funding for Protein Drug Development
•
QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100 million (USD 14.46 million) in a Series B financing round. The round was led by Bluerun Ventures, with additional participation from Taizhou Pharmaceutical Hi-tech Zone Huayin Financial Investment, Lichen Private Equity Fund, and Mingfeng Capital.…
-
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for HB0025, an in-house developed bispecific antibody (BsAb) targeting programmed-death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF). The BsAb will be assessed in combination…
-
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its adebrelimab (SHR-1316), a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The molecule is now approved for use in combination with chemotherapy to treat first-line extensive stage small-cell lung…
-
Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions
•
Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close to RMB 100 million (USD 14.46 million) in a Series A financing round. The round was led by Chengdu Tianfu International Bio-town’s fund, with additional contributions from Tao Capital. The proceeds will be directed towards…
-
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar. The approved indications for the biosimilar include the treatment of metastatic colorectal cancer (CRC), recurrent glioblastoma, and advanced metastatic or recurrent non-small cell lung cancer (NSCLC).…
-
Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing for its 9MW3911, a non-IL-2 blocking CD25 monoclonal antibody (mAb) developed via the high-efficiency B lymphocyte screening platform, has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication for this…
-
Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study
•
China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully enrolled in a confirmatory study in China for its Liwen RF ablation system, designed for the treatment of hypertrophic cardiomyopathy (HCM). This marks a significant step forward in the clinical development of this innovative device.…
-
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
•
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by Kangju Venture Capital and Tsinghua Innovation Ventures. The proceeds will be directed towards clinical studies and the development of new product…
-
HKUST and PhIRDA Sign MoU to Establish Innovation Centers
•
The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and Research Development Association (PhIRDA) have signed a Memorandum of Understanding (MoU) aimed at establishing two innovation and research centers. This strategic partnership seeks to leverage HKUST’s strengths in basic research and PhIRDA’s members’ capabilities in…
-
China Releases Blue Book on Medical Insurance Fund Supervision
•
The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book of Medical Insurance Fund Supervision: China Medical Insurance Fund Supervision and Management Development Report (2022).” This comprehensive publication provides a detailed overview of the current status, main issues, and challenges facing China’s medical insurance fund…
-
NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines
•
The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096) small-molecule COVID-19 therapy SIM0417 and Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) in the 10th version of the COVID-19 Diagnosis and Treatment Plan. Both drugs are recommended for the treatment of symptoms…
-
ClinChoice Acquires Cromsource to Expand Global CRO Footprint
•
Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l., a CRO operating out of Verona, Italy, and North Carolina in the US. Cromsource, founded in 1997, is a full-service, ISO-certified service provider that supports biotechs, pharmas, and medical device companies. Financial details of the…
-
Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment
•
China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from a Phase IIa clinical study for its lead product, ABP-671. The randomized, double-blind, placebo-controlled trial enrolled 54 patients with gout or hyperuricemia across six cohorts, with 7 randomized to ABP-671 and 2 to placebo per…
-
Echo Biotech Secures Series A++ Funding for Exosomes Drug Development
•
Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi in a Series A++ financing round. The round was led by ZBJL Capital and Yanrui Asset Management, with participation from existing investor Baidu Venture. The proceeds will be directed towards the iteration of Echo Biotech’s…
-
AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL
•
AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion of the first patient implantation in the regulatory clinical trial for its MINI WELL progressive Extended Depth-of-Focus (EDOF) intraocular lens (IOL). The procedure was successfully conducted at the EYE & ENT Hospital of Fudan University…
-
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a randomized, open, positive controlled, multi-center Phase III study. The study is designed to assess the efficacy and safety of its mitoxantrone hydrochloride liposome in patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when combined with…
-
National VBP Tender Round 8 to Be Held in Hainan with 40 Drugs Bidding
•
The National Allied Procurement Office has released a notification regarding the Round 8 of the national Volume-Based Procurement (VBP) tender program. According to the notice, the tender will be held in Hainan, with results to be released on March 29. A total of 40 drugs will participate in the price…
-
TinKer Bio Raises Series A+ Funding for Microfluidic Chip Expansion
•
China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funds will be directed towards manufacturing plant construction, CDMO business expansion, new technology and process research and development, and manufacturing capacity expansion.…
-
OcuMension Therapeutics Initiates Phase II Study for Dry Eye Treatment OT-202
•
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind, placebo-controlled Phase II clinical study. The study is designed to assess the safety and efficacy of its Category 1 drug OT-202, a tyrosine kinase inhibitor (TKI) intended for the treatment of dry eyes. This marks…
-
Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy
•
Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised over RMB 100 million (USD 14.5 million) in a Series A financing round. The round was led by Cowin Capital and Sunland Fund, with participation from Yishang Huicheng (Beijing) Investment. The proceeds will be used…
